Abstract:Due to low ability to pass through the cell membrane and lack of proof in target delivery in vivo, anti-microRNA oligonucleotide (AMO) has poor target ability to microRNA in the cytoplasm, which results in low AMO targeting efficiency and limits AMO success in vivo application. In this study, AMO-phospholipids conjugates were developed to provide the characteristics of the two phospholipids to self -assemble via hydrophilic AMO and hydrophobic phospholipid tails to overcome the AMO backbone structures and enhance the AMO delivery efficiency. This AMO-phospholipids enveloped nanoparticles was radiolabeled with technetium -99 m (99mTc) for cellular delivery and in vivo imaging. Methods: 99mTc-radiolabeled miR-155 targeted AMO with partial 2 '-O-methyl (2 '-OMe) and phosphorothioate (PS) chemical modification was prepared via the conjugation to N-hydroxysuccinimide derivative of S-acetylmercaptoacetyltriglycine (NHS-MAG3). This radiolabeled AMO is chemically conjugated with phospholipids to form AMO-phospholipid. The AMO-phospholipids served as a component of nanoparticles to embed the hydrophobic part. AMO-phospholipids fused with polycarboxybetaine (PCB) based distearoyl phosphoethanolamine-polycarboxybetaine (DSPE-PCB) modified cationic lipids to form AMO-phospholipidcoated nanoparticles (AMO-NP), which delivered AMO into cytoplasm in vitro and into tumor in vivo. Further, this radiolabeled AMO-NP was confirmed by gel electrophoresis and evaluated for its serum stability, cytotoxicity, inhibitory ability and cellular uptake in HeLa cells, as well as the fluorescent distribution in vitro. Moreover, its distribution and in vivo imaging were performed HeLa tumor -bearing mice after the injection of radiolabeled AMO-NP. Results: The gel electrophoresis of 99mTc labeled AMO-NP showed good conjugation between AMO and 99mTc. It also kept highly stable in human serum. Western blotting results showed that AMO-NP could up -regulate the expression of C/EBP beta protein, one of target proteins of miR-155 in HeLa cells, proving the ability in the specific binding and inhibition. The cellular uptake of 99mTc labeled AMO-NP was significantly higher than that of bare AMO. Furthermore, FAM labeled AMO-NP displayed its ability of specific and effective distribution in tumor cells and a good stability in cellular level. After the system administration, the distribution and in vivo imaging results revealed the significant difference between 99mTc labeled AMO-NP and negative control probe in HeLa tumor xenograft models, which suggested the specific binding and effective delivery ability of 99Tc labeled AMO-NP in vivo. Conclusion: This study supports the effectiveness and efficiency of cellular and in vivo delivery of 99mTc radiolabeled AMO-NP in cervical tumor and suggests a prospective candidate for future tumor imaging.

One-step synthesis of a radioiodinated anti-microRNA-21 oligonucleotide for theranostics in prostate tumor xenografts

Improved Synthesis and Biological Evaluation of Tc-99m Radiolabeled Amo for Mirna Imaging in Tumor Xenografts

Optimized Preparation of a 99m Tc-Radiolabeled Probe for Tracing MicroRNA

Radiolabeled AMO-phospholipid Enveloped Nanoparticle for Cellular Delivery and in Vivo Imaging in Cervical Cancer Xenografts

A Novel Tetrapeptide for Chelator-Free Radiolabeling in Optimized Preparation of 99Mtc-Radiolabeled Oligonucleotides.

Noninvasive Visualization of Microrna-155 in Multiple Kinds of Tumors Using a Radiolabeled Anti-Mirna Oligonucleotide

Study on Biodistribution and Imaging of Radioiodinated Antisense Oligonucleotides in Nude Mice Bearing Human Lymphoma

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

A proof-of-concept study on bioorthogonal-based pretargeting and signal amplify radiotheranostic strategy

[In Vivo Imaging of Breast Tumors by a 99mtc Radiolabeled Probe Targeting Microrna-155 in Mice Models].

NIR/pH-triggered aptamer-functionalized DNA origami nanovehicle for imaging-guided chemo-phototherapy

Preparation and Optimization of (99m)~Tc-radiolabeled Antisense Oligonucleotide Targeting microRNA

A Highly Specific Multiple Enhancement Theranostic Nanoprobe for PET/MRI/PAI Image-Guided Radioisotope Combined Photothermal Therapy in Prostate Cancer

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Design, Synthesis and Iodination of an Arg‐Arg‐Leu Peptide for Potential Use As an Imaging Agent for Human Prostate Carcinoma

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe

Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway

Synthesis and Preclinical Evaluation of 68Ga-MALAT-1 ASO for PET Imaging of MALAT-1 expressing Tumours

Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers.

Synthesis and Radiolabeling of (111)In-Core-cross Linked Polymeric Micelle-Octreotide for Near-Infrared Fluoroscopy and Single Photon Emission Computed Tomography Imaging.